SCHEMBL27681908

SCHEMBL27681908

O=C(NCc1ccccc1)C(c1cccc(Cl)c1)C1(O)CCC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.45
METAP2 P50579 1/20 0.44
HTT P42858 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
SLC6A2 P23975 3/20 0.43
SLC6A4 P31645 3/20 0.43
SCN5A Q14524 1/20 0.42
SCN9A Q15858 1/20 0.42
PLA2G1B P04054 2/20 0.42
ATG4B Q9Y4P1 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MASP2 O00187 1/20 0.41
HPGD P15428 1/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3954163 0.97 SLC6A2 (0.47) ADAM17METAP2SLC6A2SLC6A4
SCHEMBL3960434 0.86 MEN1 (0.46) HTTLMNAMEN1MAPTKMT2A
SCHEMBL3961259 0.86 KMT2A (0.41) MEN1MAPTKMT2ASCN5ASCN9A
SCHEMBL3955844 0.84 SLC6A2 (0.43) SLC6A2SLC6A4HPGD
SCHEMBL3951075 0.84 CYP2C9 (0.44) METAP2HTTMAPTSLC6A2SLC6A4
SCHEMBL3956055 0.83 CYP3A4 (0.43) METAP2HTTLMNAMAPTSLC6A2
SCHEMBL3952525 0.83 LMNA (0.45) HTTLMNAMEN1KMT2ASLC6A2
SCHEMBL3955939 0.83 CYP2C9 (0.42) LMNAMEN1KMT2ASCN5ASCN9A
SCHEMBL3955379 0.82 ALDH1A1 (0.43) METAP2LMNAMEN1MAPTKMT2A
SCHEMBL3980389 0.80 SLC6A2 (0.49) MEN1KMT2ASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1972920-A Arylalkyl piperazine derivatives for the treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms WYETH CORP (US) 2007-05-30 CN disclosed